Trial Profile
METAL (METformin in Advanced Lung cancer) study: PHASE II STUDY OF METFORMIN PLUS ERLOTINIB IN SECOND LINE THERAPY OF STAGE IV NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms METAL
- 27 Feb 2015 New trial record